Alkem Lab

Who are the top shareholders of the Alkem Lab?

The top shareholders of Alkem Lab include promoters, with Sarandhar Singh holding 19.42%, mutual funds at 14.97%, foreign institutional investors at 9.41%, and individual investors with a combined 15.77%. The largest public shareholder is the ICICI Prudential Multi-Asset Fund, holding 4.11%.

The top shareholders of Alkem Lab include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Sarandhar Singh holding the highest individual stake at 19.42%. Mutual funds collectively hold 14.97% of the shares through 27 different schemes, while FIIs account for 9.41% with 473 different investors. The highest public shareholder is the ICICI Prudential Multi-Asset Fund, which holds 4.11%. Additionally, individual investors have a combined holding of 15.77%.

how big is Alkem Lab?

As of Jun 06, Alkem Laboratories Ltd has a market capitalization of 58,204.24 Cr, with recent net sales of 12,756.59 Cr and net profit of 2,153.18 Cr over the last four quarters.

Market Cap: Alkem Laboratories Ltd has a market capitalization of 58,204.24 Cr and is classified as a Large Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Dec'24, Sep'24, Jun'24, and Mar'24, is 12,756.59 Cr. The sum of Net Profit for the same period is 2,153.18 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 10,312.06 Cr, while the Total Assets amount to 14,060.07 Cr.

Has Alkem Lab declared dividend?

Yes, Alkem Laboratories Ltd has declared a dividend of 1850% (₹37 per share), with an ex-date of February 14, 2025. The company has shown varying total returns over different periods, with a notable 110.91% total return over the last 5 years.

Alkem Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1850%<BR>- Amount per share: 37<BR>- Ex-date: 14 Feb 25<BR><BR>Dividend Yield: 0.87%.<BR><BR>Total Returns by Period:<BR>Over the last 6 months, the price return was -11.76%, the dividend return was 0.67%, resulting in a total return of -11.09%.<BR><BR>In the 1-year period, the price return was 1.02%, the dividend return was 0.83%, leading to a total return of 1.85%.<BR><BR>For the 2-year period, the price return was 43.8%, the dividend return was 2.56%, which resulted in a total return of 46.36%.<BR><BR>During the 3-year period, the price return was 56.49%, the dividend return was 3.90%, culminating in a total return of 60.39%.<BR><BR>In the 4-year period, the price return was 53.99%, the dividend return was 4.83%, yielding a total return of 58.82%.<BR><BR>Over the last 5 years, the price return was 103.29%, the dividend return was 7.62%, resulting in a total return of 110.91%.<BR><BR>Overall, Alkem Laboratories Ltd has declared a significant dividend, which reflects positively on the company's commitment to returning value to shareholders. The total returns over various periods show a mix of performance, with particularly strong returns over the longer term.

Who are the peers of the Alkem Lab?

Alkem Lab's peers include Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Glenmark Pharma, Glaxosmi. Pharma, Biocon, Laurus Labs, Cohance Life, and Ipca Labs. In terms of management risk, growth, and capital structure, they vary from excellent to average, with Laurus Labs showing the highest 1-year return at 76.44% and Zydus Lifesci. the lowest at -18.37%.

Peers: The peers of Alkem Lab are Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Glenmark Pharma, Glaxosmi. Pharma, Biocon, Laurus Labs, Cohance Life, and Ipca Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India and Glaxosmi. Pharma, while Good management risk is found at Zydus Lifesci., Aurobindo Pharma, Laurus Labs, Alkem Lab, and Cohance Life, and Average management risk is noted at Lupin, Glenmark Pharma, and Biocon. In terms of Growth, Excellent growth is seen at Zydus Lifesci. and Lupin, while Average growth is noted at Laurus Labs and Biocon, and Below Average growth is observed at Aurobindo Pharma, Glenmark Pharma, Alkem Lab, Glaxosmi. Pharma, and Cohance Life. For Capital Structure, Excellent capital structure is found at Zydus Lifesci., Abbott India, Aurobindo Pharma, Alkem Lab, Glaxosmi. Pharma, Cohance Life, and Ipca Labs, while Good capital structure is noted at Lupin and Glenmark Pharma, and Average capital structure is seen at Laurus Labs and Biocon.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Laurus Labs at 76.44%, while the peer with the lowest is Zydus Lifesci. at -18.37%. Alkem Lab's 1-year return is -5.54%, which is higher than Zydus Lifesci. but lower than Laurus Labs. Additionally, the peers with negative six-month returns include Zydus Lifesci., Aurobindo Pharma, and Glenmark Pharma.

Who are in the management team of Alkem Lab?

As of March 2023, the management team of Alkem Lab includes Basudeo N Singh (Executive Chairman), Sandeep Singh (Managing Director), and several Executive and Non-Executive Directors, along with the Company Secretary, Manish Narang, who collectively guide the company's governance and strategy.

As of March 2023, the management team of Alkem Lab includes the following individuals:<BR><BR>1. Basudeo N Singh - Executive Chairman<BR>2. Sandeep Singh - Managing Director<BR>3. Mritunjay Kumar Singh - Executive Director<BR>4. Sarvesh Singh - Executive Director<BR>5. Madhurima Singh - Executive Director<BR>6. Srinivas Singh - Executive Director<BR>7. A K Purwar - Non-Executive & Independent Director<BR>8. Sangeeta Kapiljit Singh - Non-Executive & Independent Director<BR>9. Sudha Ravi - Non-Executive & Independent Director<BR>10. Dheeraj Sharma - Non-Executive & Independent Director<BR>11. Narendra Aneja - Non-Executive & Independent Director<BR>12. Sujjain Talwar - Independent Director<BR>13. Manish Narang - Company Secretary & Compliance Officer<BR><BR>This diverse team plays a crucial role in the governance and strategic direction of the company.

What does Alkem Lab do?

Alkem Laboratories Ltd is a prominent Indian pharmaceutical company founded in 1973, specializing in the development and sale of pharmaceutical and nutraceutical products. As of March 2025, it reported net sales of ₹31,438 Cr and a net profit of ₹3,059 Cr, with a market capitalization of ₹59,352 Cr.

Overview:<BR>Alkem Laboratories Ltd is a leading Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Large Cap company.<BR><BR>History:<BR>Alkem Laboratories Ltd was incorporated in the year 1973. The latest quarterly results reported are for March 2025, showcasing the company's ongoing operations in the pharmaceutical sector.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 31,438 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3,059 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 59,352 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.85% <BR>Debt-Equity: -0.09 <BR>Return on Equity: 18.07% <BR>Price to Book: 4.92 <BR><BR>Contact Details:<BR>Address: Alkem House Senapati Bapat Marg, Lower Parel Mumbai Maharashtra : 400013 <BR>Tel: 91-22-39829999 <BR>Email: investors@alkem.com <BR>Website: http://www.alkemlabs.com

When is the next results date for Alkem Lab?

Alkem Lab will announce its results on 12 August 2025.

Alkem Lab will declare its results on 12 August 2025.

Is Alkem Lab overvalued or undervalued?

As of November 13, 2025, Alkem Lab is fairly valued with a PE ratio of 30.06 and solid financial metrics, despite recent stock performance lagging behind the Sensex.

As of 13 November 2025, the valuation grade for Alkem Lab has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 30.06, a Price to Book Value of 5.70, and an EV to EBITDA ratio of 25.45. In comparison to its peers, Sun Pharma has a higher PE ratio of 36.15 and an EV to EBITDA of 23.85, while Cipla is more attractively valued with a PE of 22.65 and an EV to EBITDA of 16.03.<BR><BR>Alkem Lab's financial metrics indicate a solid performance, with a ROCE of 19.77% and a ROE of 18.07%. Despite recent stock performance lagging behind the Sensex over one year (2.53% vs. 8.74%), the company's strong ratios suggest it is positioned well within the pharmaceuticals sector. Overall, Alkem Lab appears to be fairly valued in the current market context.

How has been the historical performance of Alkem Lab?

Alkem Lab has shown consistent growth in net sales and profits, with net sales increasing from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025, and profit after tax rising from 1,149.31 Cr to 2,216.00 Cr during the same period, indicating strong financial performance.

Answer:<BR>The historical performance of Alkem Lab shows a consistent growth trend in net sales and profits over the years, culminating in significant figures for the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Alkem Lab's net sales increased from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025. The company's operating profit (PBDIT) also saw growth, reaching 3,005.89 Cr in March 2025, up from 1,577.61 Cr in March 2020. Profit before tax increased from 1,259.79 Cr in March 2020 to 2,527.03 Cr in March 2025, while profit after tax rose from 1,149.31 Cr to 2,216.00 Cr over the same period. The earnings per share (EPS) improved significantly from 94.28 in March 2020 to 181.14 in March 2025. On the balance sheet, total assets grew from 9,012.97 Cr in March 2020 to 15,952.85 Cr in March 2025, and total liabilities increased from 9,012.97 Cr to 15,952.85 Cr during the same timeframe. Cash flow from operating activities also showed an upward trend, reaching 1,912.00 Cr in March 2025, although the net cash outflow was recorded at -186.00 Cr. Overall, Alkem Lab has demonstrated robust growth in sales, profits, and assets over the years, indicating a strong financial performance.

Is Alkem Lab technically bullish or bearish?

As of December 1, 2025, Alkem Lab's technical trend is mildly bullish, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Alkem Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with no clear monthly trend. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some bearish signals in the monthly indicators.

Are Alkem Laboratories Ltd latest results good or bad?

Alkem Laboratories Ltd's latest results are mixed; while net sales grew 10.74% year-over-year, there was a 6.60% sequential decline, and net profit fell 16.87% from the previous quarter, raising concerns about sustainability and impacting investor sentiment.

Alkem Laboratories Ltd's latest results present a mixed picture. For Q3 FY26, the company reported net sales of ₹3,736.82 crores, which reflects a solid year-over-year growth of 10.74%. However, this represents a sequential decline of 6.60% from the previous quarter, indicating some challenges in maintaining momentum.<BR><BR>The net profit for the quarter was ₹636.02 crores, showing a slight year-over-year increase of 1.63%, but it experienced a significant sequential drop of 16.87%. This decline in profit, coupled with margin pressures—operating margin decreased to 22.16% and PAT margin fell to 17.49%—suggests that the company is facing operational headwinds, particularly from rising costs and competitive pricing dynamics.<BR><BR>While the nine-month performance for FY26 shows stronger overall growth with a 12.96% increase in net sales and a 10.73% rise in net profit compared to the same period last year, the recent quarterly results raise concerns about the sustainability of this growth. The market has reacted negatively, with the stock underperforming against benchmarks following the announcement.<BR><BR>In summary, while Alkem Laboratories has demonstrated resilience and growth over the longer term, the latest quarterly results indicate some challenges that could affect investor sentiment and future performance.

Should I buy, sell or hold Alkem Laboratories Ltd?

Why is Alkem Laboratories Ltd falling/rising?

As of 17-Mar, Alkem Laboratories Ltd's stock price is rising, currently at 5,332.00, following a trend reversal after four days of decline and increased investor participation. Despite trading below moving averages, the stock has shown strong long-term performance with a 10.70% return over the past year, outperforming the Sensex.

As of 17-Mar, Alkem Laboratories Ltd's stock price is rising, evidenced by a current price of 5,332.00, which reflects an increase of 10.4 (0.2%). This upward movement comes after a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 50.52% against the five-day average, indicating growing interest among investors.<BR><BR>Despite the recent gains, the stock has been trading lower than its moving averages across various time frames, which may suggest underlying weaknesses. However, the stock's performance over the past year has been strong, generating a return of 10.70%, outperforming the Sensex, which has only increased by 2.56% during the same period. Furthermore, Alkem Laboratories has demonstrated high management efficiency with a return on equity (ROE) of 16.90% and maintains a low debt-to-equity ratio, which are positive indicators for investors.<BR><BR>In summary, the stock's rise can be attributed to a recent trend reversal, increased investor participation, and strong long-term performance relative to benchmarks, despite some concerns regarding its moving averages and long-term growth rates.

Why is Alkem Laboratories Ltd falling/rising?

As of 18-Mar, Alkem Laboratories Ltd's stock price is declining, currently at 5,331.60, due to underperformance against its sector, trading below moving averages, and decreased investor participation. Concerns over long-term growth prospects further contribute to this downward trend.

As of 18-Mar, Alkem Laboratories Ltd's stock price is experiencing a slight decline, currently at 5,331.60, reflecting a change of -2.5 (-0.05%). This decrease can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has underperformed its sector today by -0.32%, indicating weaker performance relative to its peers. Additionally, it is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend.<BR><BR>Investor participation has also decreased, with a delivery volume of 77.8k on 17 March falling by -30.31% compared to the 5-day average. This decline in trading activity may signal reduced investor confidence or interest in the stock.<BR><BR>While the company has demonstrated strong management efficiency with a high return on equity (ROE) of 16.90% and maintains a low debt-to-equity ratio, these positive factors are overshadowed by concerns regarding long-term growth. The operating profit has only grown at an annual rate of 8.21% over the past five years, which is relatively modest. Furthermore, recent financial results have shown flat performance, with cash and cash equivalents at their lowest and a declining debtors turnover ratio.<BR><BR>In summary, the combination of underperformance against benchmarks, declining investor participation, and concerns over long-term growth prospects are contributing to the current downward movement in Alkem Laboratories Ltd's stock price.

Why is Alkem Laboratories Ltd falling/rising?

As of 19-Mar, Alkem Laboratories Ltd's stock price is falling to 5,235.00, reflecting a 2.12% decrease. The stock is trading below all key moving averages and has seen reduced investor participation, indicating a bearish trend despite strong long-term performance.

As of 19-Mar, Alkem Laboratories Ltd's stock price is falling, currently at 5,235.00, which reflects a decrease of 113.6 or 2.12%. This decline follows a trend where the stock has fallen after two consecutive days of gains. The stock's performance today is in line with the sector, which has also seen a decrease of 2.11%. <BR><BR>In terms of moving averages, Alkem Laboratories is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume on March 18 falling by 62.05% compared to the 5-day average. <BR><BR>Despite having a strong long-term performance, with a 68.07% increase over three years and a 99.27% increase over five years, the stock has shown poor short-term growth, with a 4.91% decline year-to-date. The company's operating profit growth has also been modest, at an annual rate of 8.21% over the last five years, contributing to concerns about its long-term growth potential. <BR><BR>Overall, the combination of a declining stock price, reduced investor participation, and modest growth metrics are contributing to the current downward movement in Alkem Laboratories Ltd's stock price.

Why is Alkem Laboratories Ltd falling/rising?

As of 20-Mar, Alkem Laboratories Ltd's stock price is rising at 5,284.50, but it is underperforming its sector and trading below key moving averages, indicating potential short-term weakness. Despite a 7.92% return over the past year, concerns about long-term growth persist due to slow operating profit growth and recent flat results.

As of 20-Mar, Alkem Laboratories Ltd's stock price is rising, currently at 5,284.50, with a change of 43.7 (0.83%) upward. The stock opened with a gain of 2.51% today and reached an intraday high of Rs 5,372.4. Despite this positive movement, the stock has underperformed its sector by 0.87% today and is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a potential weakness in the short-term trend.<BR><BR>In terms of long-term performance, Alkem Laboratories has shown resilience, generating a return of 7.92% over the past year, which is significantly better than the Sensex's decline of 2.38% during the same period. Additionally, the company has demonstrated high management efficiency with a return on equity (ROE) of 16.90% and a low debt-to-equity ratio, which are positive indicators for investors.<BR><BR>However, there are concerns regarding the company's long-term growth potential, as its operating profit has only grown at an annual rate of 8.21% over the last five years. Furthermore, the recent flat results in December, with cash and cash equivalents at their lowest and a declining debtors turnover ratio, may contribute to cautious sentiment among investors.<BR><BR>Overall, while the stock is currently experiencing a rise, the mixed signals from its performance metrics and market conditions suggest that investors should remain vigilant about its long-term growth prospects.

Why is Alkem Laboratories Ltd falling/rising?

As of 23-Mar, Alkem Laboratories Ltd's stock price is at 5,145.00, down 2.14%, reflecting high volatility and negative market sentiment in the Pharmaceuticals & Drugs sector. Despite increased investor participation, the company's weak long-term growth prospects and low financial metrics contribute to the stock's decline.

As of 23-Mar, Alkem Laboratories Ltd's stock price is falling, currently at 5,145.00, reflecting a decrease of 112.75 (-2.14%). The stock has shown a negative performance today, despite initially opening with a gain of 4.25% and reaching an intraday high of Rs 5,481.05. However, it also touched a low of Rs 5,116.05, indicating high volatility with an intraday fluctuation of 6.19%.<BR><BR>In the context of broader market performance, the Pharmaceuticals & Drugs sector has declined by 3.58%, contributing to the downward pressure on Alkem's stock. Additionally, the stock is trading below its moving averages across various time frames, which typically signals weakness in price momentum.<BR><BR>While there has been a notable increase in investor participation, with delivery volume rising by 183.05% against the 5-day average, the overall sentiment appears to be negative. This is further compounded by the company's poor long-term growth prospects, as indicated by an operating profit growth rate of only 8.21% over the last five years. Furthermore, the company's cash and cash equivalents are at their lowest, and the debtors turnover ratio is also at a low point, which may raise concerns among investors.<BR><BR>Overall, despite some positive factors such as high management efficiency and institutional holdings, the current market conditions and the company's financial metrics suggest that Alkem Laboratories Ltd is experiencing a decline in its stock price.

Why is Alkem Laboratories Ltd falling/rising?

As of 24-Mar, Alkem Laboratories Ltd's stock price is rising to 5,305.25, up 3.1%, driven by strong relative performance and high management efficiency. Despite a decline in investor participation, the stock remains liquid and has shown positive long-term returns, indicating investor confidence.

As of 24-Mar, Alkem Laboratories Ltd's stock price is rising, currently at 5,305.25, reflecting a change of 159.65 (3.1%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.98% today, indicating strong relative performance. Additionally, it reached an intraday high of Rs 5307.25, which is a 3.14% increase.<BR><BR>Despite a recent decline in investor participation, with delivery volume falling by 50.02% against the 5-day average, the stock remains liquid enough for trading, with a value of Rs 1.52 crore based on 2% of the 5-day average traded value. Furthermore, Alkem Laboratories Ltd has demonstrated high management efficiency, evidenced by a return on equity (ROE) of 16.90%, and it maintains a low debt-to-equity ratio, which is favorable for investors.<BR><BR>In terms of long-term performance, the stock has shown a positive trajectory, generating a 4.85% return over the past year and outperforming the BSE500 index over the last three years. This strong historical performance, combined with high institutional holdings at 31.51%, suggests that informed investors have confidence in the company's fundamentals.<BR><BR>Overall, the combination of today's positive performance, strong management efficiency, and favorable long-term returns contributes to the rising stock price of Alkem Laboratories Ltd.

Why is Alkem Laboratories Ltd falling/rising?

As of 25-Mar, Alkem Laboratories Ltd's stock price is rising to 5,436.00, reflecting a 2.6% increase. This upward trend is supported by strong fundamentals, recent performance, and positive market sentiment, despite some long-term growth concerns.

As of 25-Mar, Alkem Laboratories Ltd's stock price is rising, currently at 5,436.00, reflecting a change of 137.8 (2.6%) upward. This increase can be attributed to several factors. The stock has outperformed its sector by 0.71% today and has been on a consecutive gain for the last two days, accumulating a total return of 5.64% during this period. Additionally, the stock reached an intraday high of Rs 5464.35, marking a 3.14% increase.<BR><BR>In terms of performance relative to benchmarks, Alkem Laboratories has shown resilience, with a 1-week return of +1.63% compared to a -1.87% decline in the Sensex. Over the past year, the stock has generated an 8.59% return, significantly outperforming the BSE500 over various time frames, including 3 years and 1 year.<BR><BR>The company's strong fundamentals also support the rising stock price. It boasts a high return on equity (ROE) of 16.90% and a low debt-to-equity ratio, indicating financial stability. Furthermore, high institutional holdings at 31.51% suggest confidence from larger investors who typically have better analytical resources.<BR><BR>Despite some concerns regarding long-term growth, such as a modest operating profit growth rate of 8.21% over the last five years, the current upward momentum in stock price is primarily driven by recent performance, strong fundamentals, and positive market sentiment.

Which are the latest news on Alkem Lab?